Company / Cash & Equivalents
Immunocore Holdings plc Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$467.7M
FY2025
5-year range
$402.5M / $467.7M
FY2022-FY2025
Trend
+2.6%
vs FY2024
Sector context
#45 of 207
Health Care
What the data says
Immunocore Holdings plc's cash & equivalents of $468M is higher than 78% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $402M in FY2022 to $468M in FY2025.
Based on SEC 10-K filings.
$468M in FY2025 with a 3-year CAGR of +5.1%. Top quartile in the Health Care sector.
Improved from $443M to $468M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +5.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-30.1% below sector average
Key checks
Key Insights
- Immunocore Holdings plc's cash & equivalents has grown for 3 consecutive years.
- 3-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 2.6% year-over-year.
- Ranks #45 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $467.7M | +2.6% |
| FY2024 | $455.7M | +3.0% |
| FY2023 | $442.6M | +10.0% |
| FY2022 | $402.5M | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026